The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis
Open accessAbstract
BACKGROUND & AIMS: Similarities in the hepatic responses to obesity and ethanol exposure suggest that these conditions evoke common pathogenic mechanisms. Thus, it is possible that ethanol exposure is increased in obesity. Given that intestinal bacteria can produce ethanol, the aim of this study was to determine if the intestinal production of ethanol is increased in obesity. METHODS: Breath was collected from genetically obese, ob/ob male C57BL/6 mice and lean male littermates at different ages (14, 20, and 24 weeks) and times of the day (9 AM, 3 PM, and 9 PM). Obese mice (24 weeks old) were then treated with neomycin (1 mg/mL) for 5 days, and sampling was repeated. RESULTS: Breath collected in the morning from 24-week-old obese mice had a higher ethanol content than breath from their lean littermates (271 vs. 78 pmol/mL CO(2); P < 0.0001). Subsequent studies in 14- and 20-week-old mice showed that exhaled ethanol increased with age in obese (from 26 to 107 pmol/mL CO(2); P < 0. 002) but not lean (29 and 12 pmol/mL CO(2)) mice and was greater in older obese mice than in older lean mice (P < 0.0006). Obese mice showed a diurnal increase in breath ethanol in the morning that decreased through the afternoon and evening (107 to 33 to 13 pmol/mL CO(2)). Neomycin treatment decreased morning breath ethanol levels by 50% (from 220 to 110 pmol/mL CO(2); P < 0.0003). CONCLUSIONS: Even in the absence of ethanol ingestion, ethanol can be detected in exhaled breath. In obesity, an age-related increase in breath ethanol content reflects increased production of ethanol by the intestinal microflora. Hence, intestinal production of ethanol may contribute to the genesis of obesity-related fatty liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535
Effects of the obese Gene Product on Body Weight Regulation in ob / ob Mice
Pelleymounter, M. A., Cullen, M. J., Baker, M. B., Hecht, R., Winters, D., Boone, T., & Collins, F. (1995) · Science · doi:10.1126/science.7624776 · Cited by 4,017
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Pi-Sunyer, F. X. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-7_part_2-199310011-00006 · Cited by 1,371
Kern, P. A., Saghizadeh, M., Ong, J. M., Bosch, R. J., Deem, R., & Simsolo, R. B. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117899 · Cited by 1,305
Cited by
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
Self-citationDiagnostic potential of breath analysis—focus on volatile organic compounds
Miekisch, W., Schubert, J. K., & Noeldge-Schomburg, G. F. E. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.04.023 · Cited by 1,096
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971
Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P. A., Moser, A. B., DeSimone, C., Song, X.-Y., & Diehl, A. M. (2003) · Hepatology · doi:10.1053/jhep.2003.50048 · Cited by 930
Self-citationNonalcoholic fatty liver disease
Clark, J. M., Brancati, F. L., & Diehl, A. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.33573 · Cited by 901
Self-citationPathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678
Raman, M., Ahmed, I., Gillevet, P. M., Probert, C. S., Ratcliffe, N. M., Smith, S., Greenwood, R., Sikaroodi, M., Lam, V., Crotty, P., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.015 · Cited by 672
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella Pneumoniae
Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., Zhao, X., Li, N., Li, S., Xue, G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.018 · Cited by 548
Paradis, V., Perlemuter, G., Bonvoust, F., Dargere, D., Parfait, B., Vidaud, M., Conti, M., Huet, S., Ba, N., Buffet, C., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.28055 · Cited by 542
Gut microbiota and metabolic syndrome
Festi, D., Schiumerini, R., Eusebi, L. H., Marasco, G., Taddia, M., & Colecchia, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16079 · Cited by 534
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
Gut microbiome and liver diseases
Tilg, H., Cani, P. D., & Mayer, E. A. (2016) · Gut · doi:10.1136/gutjnl-2016-312729 · Cited by 525
The role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523
Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin
Bergheim, I., Weber, S., Vos, M., Krämer, S., Volynets, V., Kaserouni, S., McClain, C. J., & Bischoff, S. C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.035 · Cited by 522
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)
Safari, Z., & Gérard, P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03011-w · Cited by 502
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
Chopyk, D. M., & Grakoui, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.077 · Cited by 490
Alisi, A., Bedogni, G., Baviera, G., Giorgio, V., Porro, E., Paris, C., Giammaria, P., Reali, L., Anania, F., & Nobili, V. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12758 · Cited by 471
The role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Role of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
Intestinal Permeability Defects: Is It Time to Treat?
Odenwald, M. A., & Turner, J. R. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.001 · Cited by 366
“Strong association in mice.(99,100) Unknown”
Gut microbiota: a new path to treat obesity
on behalf of the Obesity Programs of nutrition, E., Muscogiuri, G., Cantone, E., Cassarano, S., Tuccinardi, D., Barrea, L., Savastano, S., & Colao, A. (2019) · International Journal of Obesity Supplements · doi:10.1038/s41367-019-0011-7 · Cited by 354
Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
Chen, J., & Vitetta, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155214 · Cited by 352
Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease
Michail, S., Lin, M., Frey, M. R., Fanter, R., Paliy, O., Hilbush, B., & Reo, N. V. (2015) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiu002 · Cited by 336
Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Manne, V., Handa, P., & Kowdley, K. V. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.007 · Cited by 335
Small Intestinal Bacterial Overgrowth: Roles of Antibiotics, Prebiotics, and Probiotics
Quigley, E. M. M., & Quera, R. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.046 · Cited by 329
Gut–liver axis, nutrition, and non-alcoholic fatty liver disease
Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.06.023 · Cited by 327
“synthesis of triglycerides in the liver [8, 9]; modulation of endocannabinoid system [10, 11]; modulation of choline metabolism (which is required for very-low-density lipoprotein synthesis and hepatic lipid export) [12, 13]; modulation of bile acid homeostasis [14, 15]; the ability to generate endogenous ethanol [16,…”
BackgroundUpdate on Nonalcoholic Fatty Liver Disease
McCullough, A. J. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200203000-00013 · Cited by 315
Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease
Åberg, F., Byrne, C. D., Pirola, C. J., Männistö, V., & Sookoian, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.030 · Cited by 307
Volynets, V., Küper, M. A., Strahl, S., Maier, I. B., Spruss, A., Wagnerberger, S., Königsrainer, A., Bischoff, S. C., & Bergheim, I. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2112-9 · Cited by 268
Microbiome-derived ethanol in nonalcoholic fatty liver disease
Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02016-6 · Cited by 215
LeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
“Earlier reports showed that intestinal barrier dysfunction plays a causal role in MASLD [160, 245–248].”
BackgroundYu, J., Marsh, S., Hu, J., Feng, W., & Wu, C. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/2862173 · Cited by 199
Gut microbiota and probiotics in chronic liver diseases
Cesaro, C., Tiso, A., Del Prete, A., Cariello, R., Tuccillo, C., Cotticelli, G., del Vecchio Blanco, C., & Loguercio, C. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.015 · Cited by 182
Spruss, A., & Bergheim, I. (2009) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.05.006 · Cited by 162
Toll-like Receptor 4 and Hepatic Fibrogenesis
Pradere, J.-P., Troeger, J., Dapito, D., Mencin, A., & Schwabe, R. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255353 · Cited by 158
The gut microbiota and the metabolic health of the host
Joyce, S. A., & Gahan, C. G. M. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000039 · Cited by 147
Ballway, J. W., & Song, B.-J. (2021) · Antioxidants · doi:10.3390/antiox10030384 · Cited by 72
Visschers, R. G. J., Luyer, M. D., Schaap, F. G., Olde Damink, S. W. M., & Soeters, P. B. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32836410a4 · Cited by 60
Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies
Koning, M., Herrema, H., Nieuwdorp, M., & Meijnikman, A. S. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2226922 · Cited by 56
Metadata
- Authors
- Cope, K., Risby, T., & Diehl, A. M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 119
- Issue
- 5
- Pages
- 1340-1347
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2025852204
- Cited by
- 357
- References
- 49
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.